Molgramostim is a Savara program in autoimmune pulmonary alveolar proteinosis (aPAP) BLA. Its PDUFA date is Nov 22, 2026, the FDA's goal date to complete review of the application. Every date links its source.
All upcoming FDA decision dates on the 2026 PDUFA calendar
Molgramostim is marketed as MOLBREEVI (molgramostim inhalation); the events below include those tracked under the brand name. Indication under review: Autoimmune pulmonary alveolar proteinosis (aPAP) BLA. Sponsor: Savara (SVRA). Market-cap tier at the time we tracked it: Small. We track 2 catalyst events for this program: 2 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.
| Fund | Shares | Value at quarter end | Filing |
|---|---|---|---|
| RTW Investments | 5,952,380 | $36.7 million | filed August 14, 2026 |
| OrbiMed Advisors | 3,959,900 | $24.4 million | filed August 14, 2026 |
13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.
Molgramostim's PDUFA date is Nov 22, 2026. That is the FDA's goal date to complete review of the application; the agency can act earlier or extend it.
No FDA decision for Molgramostim is in our archive yet.
In our records Molgramostim is under review or in development for Autoimmune pulmonary alveolar proteinosis (aPAP) BLA.
Savara (SVRA).
FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.